Ezallor Sprinkle Patent Expiration

Ezallor Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 1 US drug patent filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 12, 2036. Details of Ezallor Sprinkle's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 Stable multiparticulate pharmaceutical composition of rosuvastatin
Feb, 2036

(11 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Ezallor Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ezallor Sprinkle's family patents as well as insights into ongoing legal events on those patents.

Ezallor Sprinkle's family patents


Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Ezallor Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 12, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Ezallor Sprinkle Generics:

Rosuvastatin Calcium is the generic name for the brand Ezallor Sprinkle. 27 different companies have already filed for the generic of Ezallor Sprinkle, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ezallor Sprinkle's generic





About Ezallor Sprinkle

Ezallor Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. Ezallor Sprinkle uses Rosuvastatin Calcium as an active ingredient. Ezallor Sprinkle was launched by Sun Pharm in 2018.

Can you believe Ezallor Sprinkle received compensation for the extended wait time during the regulatory approval process?

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

Market Authorisation Date:

Ezallor Sprinkle was approved by FDA for market use on 18 December, 2018.

Active Ingredient:

Ezallor Sprinkle uses Rosuvastatin Calcium as the active ingredient. Check out other Drugs and Companies using Rosuvastatin Calcium ingredient

Dosage:

Ezallor Sprinkle is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 40MG BASE CAPSULE Discontinued ORAL
EQ 5MG BASE CAPSULE Discontinued ORAL
EQ 20MG BASE CAPSULE Discontinued ORAL
EQ 10MG BASE CAPSULE Discontinued ORAL